Illumina announced its definitive agreement to acquire proteomics technology company SomaLogic from Standard BioTools for an upfront $350 million in cash plus up to $75 million in near-term performance payments and royalties. SomaLogic’s patented SOMAmer reagents and proteomic assays complement Illumina’s genomics platforms, enhancing capabilities in biomarker discovery and disease profiling. This acquisition aims to accelerate Illumina’s multiomics roadmap, leveraging next-generation sequencing-based proteomics solutions to provide more comprehensive biological insights for research and clinical applications. The transaction includes SomaLogic’s Boulder laboratory and staff, and follows years of close collaboration between the companies.